The aim of this single center, single arm and prospective study is to explore the safety and efficacy of hDMSCs in the treatment of radiation pneumonitis.

Start Date10 Sep 2023

Sponsor / Collaborator

Sichuan University

ChiCTR2300075235 / RecruitingPhase 1IIT

Safety and efficacy of dead mesenchymal stem cells in the treatment of osteoarthritis

Start Date01 Sep 2023

Sponsor / Collaborator-

100 Clinical Results associated with Death mesenchymal stem cell(Sichuan University)

100 Translational Medicine associated with Death mesenchymal stem cell(Sichuan University)

100 Patents (Medical) associated with Death mesenchymal stem cell(Sichuan University)

Literatures (Medical) associated with Death mesenchymal stem cell(Sichuan University)

01 Apr 2014·BiomaterialsQ1 · ENGINEERING & TECHNOLOGY

The immunosuppressive properties of non-cultured dermal-derived mesenchymal stromal cells and the control of graft-versus-host disease

Q1 · ENGINEERING & TECHNOLOGY

Article

Author: Tan, Li ; Gao, Li ; Shi, Chunmeng ; Liu, Fei ; Chen, Zelin ; Liu, Tao

Mesenchymal stromal cells (MSCs) have been developed for the prevention and treatment of graft-versus-host disease (GVHD). Non-cultured natural MSCs are considered ideal, as they better maintain their biological and therapeutic properties. The skin is the largest organ in the body and constitutes an interesting alternative to bone marrow for the generation of MSCs. Large numbers of dermal-derived-MSCs (DMSCs) can be easily generated without culturing in vitro, but their therapeutic effects still remain unclear. In this study, we described for the first time the use of non-cultured DMSCs for controlling GVHD in an MHC-mismatched mouse model and investigated their immunomodulatory effects. Our results showed that non-cultured mouse DMSCs decreased the incidence and severity of acute GVHD during MHC-mismatched stem cell transplantation in mice. This effect was mediated by the inhibition of splenic cell (SPC) proliferation and the enhancement of Treg cells. Consistent with the results in vivo, the results in vitro showed that human DMSCs inhibited the proliferation of peripheral blood mononuclear cells (PBMCs) by inhibiting the proliferation of CD3(+) T cells. hDMSCs prevented PBMCs from entering S phase, suppressed the activation of CD3(+) T cells and increased Treg proportions. In conclusion, DMSCs should be considered as a novel MSC source for the control of refractory GVHD.

100 Deals associated with Death mesenchymal stem cell(Sichuan University)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lung Injury	Phase 2	CN	Sichuan University	10 Sep 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Death mesenchymal stem cell(Sichuan University)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation